Clinical Trial Update: Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI. [Phase 2]

View source ↗

Summary

Phase 2 trial update for lazertinib in NSCLC patients with asymptomatic or mild brain metastases after EGFR TKI failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Neoplasms

Drugs mentioned

• Lazertinib (lazertinib)

Snippet

Sponsor: Jin Hyoung Kang | Conditions: Lung Neoplasms | Phase 2 | Status: UNKNOWN